STRS Ohio’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.8M Sell
28,557
-3,099
-10% -$2.11M 0.07% 286
2026
Q1
$24.5M Sell
31,656
-1,340
-4% -$1.03M 0.1% 206
2025
Q4
$25.5M Sell
32,996
-2,589
-7% -$1.76M 0.1% 213
2025
Q3
$20M Sell
35,585
-865
-2% -$489K 0.07% 275
2025
Q2
$19.1M Buy
36,450
+2,069
+6% +$1.15M 0.07% 299
2025
Q1
$21.8M Buy
34,381
+725
+2% +$499K 0.09% 256
2024
Q4
$24M Sell
33,656
-3,964
-11% -$3.33M 0.1% 243
2024
Q3
$39.5M Sell
37,620
-200
-0.5% -$223K 0.15% 157
2024
Q2
$39.7M Buy
37,820
+24
+0.1% +$23.3K 0.16% 147
2024
Q1
$36.4M Buy
37,796
+3,704
+11% +$3.52M 0.14% 169
2023
Q4
$29.9M Buy
34,092
+2,837
+9% +$2.34M 0.12% 193
2023
Q3
$25.7M Sell
31,255
-977
-3% -$768K 0.11% 214
2023
Q2
$23.2M Sell
32,232
-1,473
-4% -$1.14M 0.1% 231
2023
Q1
$27.7M Sell
33,705
-333
-1% -$251K 0.12% 213
2022
Q4
$24.6M Sell
34,038
-809
-2% -$597K 0.11% 234
2022
Q3
$24M Sell
34,847
-1,163
-3% -$732K 0.11% 217
2022
Q2
$21.3M Sell
36,010
-4,639
-11% -$3.02M 0.1% 250
2022
Q1
$28.4M Buy
40,649
+4,439
+12% +$2.81M 0.1% 232
2021
Q4
$22.9M Sell
36,210
-9,194
-20% -$5.65M 0.08% 281
2021
Q3
$27.5M Sell
45,404
-3,069
-6% -$1.91M 0.1% 239
2021
Q2
$27.1M Buy
48,473
+533
+1% +$270K 0.1% 246
2021
Q1
$22.7M Sell
47,940
-6,894
-13% -$3.36M 0.09% 267
2020
Q4
$26.5M Buy
54,834
+5,003
+10% +$2.7M 0.1% 239
2020
Q3
$27.9M Sell
49,831
-2,525
-5% -$1.53M 0.12% 200
2020
Q2
$32.7M Buy
52,356
+9,434
+22% +$5.35M 0.14% 171
2020
Q1
$21M Buy
42,922
+1,569
+4% +$647K 0.11% 210
2019
Q4
$15.5M Sell
41,353
-3,082
-7% -$1.04M 0.07% 313
2019
Q3
$12.3M Sell
44,435
-1,546
-3% -$457K 0.05% 336
2019
Q2
$14.4M Buy
45,981
+264
+0.6% +$87.9K 0.06% 314
2019
Q1
$18.8M Buy
45,717
+893
+2% +$368K 0.09% 273
2018
Q4
$16.7M Buy
44,824
+1,110
+3% +$406K 0.09% 279
2018
Q3
$17.7M Sell
43,714
-3,486
-7% -$1.33M 0.08% 294
2018
Q2
$16.3M Sell
47,200
-1,332
-3% -$417K 0.07% 303
2018
Q1
$16.7M Sell
48,532
-840
-2% -$292K 0.07% 294
2017
Q4
$18.6M Sell
49,372
-722
-1% -$292K 0.08% 284
2017
Q3
$22.4M Hold
50,094
0.1% 263
2017
Q2
$24.6M Sell
50,094
-1,589
-3% -$695K 0.11% 247
2017
Q1
$20M Sell
51,683
-8,159
-14% -$3.02M 0.09% 285
2016
Q4
$22M Buy
59,842
+13,589
+29% +$5.17M 0.1% 259
2016
Q3
$18.6M Sell
46,253
-1,435
-3% -$576K 0.08% 291
2016
Q2
$16.7M Sell
47,688
-9,839
-17% -$3.79M 0.07% 307
2016
Q1
$20.7M Sell
57,527
-9,888
-15% -$4.07M 0.09% 259
2015
Q4
$36.6M Buy
67,415
+106
+0.2% +$57.4K 0.16% 170
2015
Q3
$31.3M Buy
67,309
+246
+0.4% +$132K 0.15% 186
2015
Q2
$34.2M Sell
67,063
-130
-0.2% -$63.4K 0.15% 195
2015
Q1
$30.3M Sell
67,193
-1,211
-2% -$513K 0.13% 223
2014
Q4
$28.1M Buy
68,404
+828
+1% +$326K 0.12% 229
2014
Q3
$24.4M Hold
67,576
0.11% 252
2014
Q2
$19.1M Sell
67,576
-3,785
-5% -$1.12M 0.09% 297
2014
Q1
$21.4M Sell
71,361
-1,300
-2% -$401K 0.1% 264
2013
Q4
$20M Buy
72,661
+2,200
+3% +$633K 0.09% 277
2013
Q3
$22M Buy
70,461
+10,825
+18% +$2.85M 0.1% 278
2013
Q2
$13.4M Buy
+59,636
New +$13.9M 0.06% 369

Other funds holding REGN

STRS Ohio's REGN Position: Q2 2026 in Review

STRS Ohio reduced its Regeneron Pharmaceuticals (REGN) stake by 9.8% in Q2 2026, selling an estimated $2.11M and leaving 28,557 shares worth $17.8M. The position accounts for 0.07% of the portfolio, ranked #286.

STRS Ohio first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $39.7M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • STRS Ohio held 28,557 shares of Regeneron Pharmaceuticals worth $17.8M as of Q2 2026.
  • STRS Ohio sold 3,099 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Regeneron Pharmaceuticals made up 0.07% of STRS Ohio's portfolio in Q2 2026, its #286 holding.
  • STRS Ohio first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • STRS Ohio's Regeneron Pharmaceuticals position peaked at $39.7M in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.